U.S. to begin offering COVID-19 vaccine booster shots in September
Send a link to a friend
[August 19, 2021]
By Carl O'Donnell and Ahmed Aboulenein
(Reuters) - COVID-19 vaccine booster shots
will be made widely available to Americans starting on Sept. 20, U.S.
health officials said on Wednesday, citing data showing diminishing
protection from the initial vaccinations as infections rise from the
Delta variant.
U.S. officials will offer a third shot to Americans who received their
initial inoculation of two-dose COVID-19 vaccines made by Moderna Inc
and by Pfizer Inc and BioNTech AG at least eight months earlier, the
Department of Health and Human Services said in a statement .
"It’s the best way to protect ourselves from new variants that may
arise," U.S. President Joe Biden told reporters at the White House. "It
will make you safer and for longer. It will help end this pandemic
faster."
The U.S. government expects to give out 100 million booster shots for
free at around 80,000 locations nationwide, Biden said.

Initial booster doses will be given to Americans who received two-dose
vaccines, but officials said they anticipate that people given Johnson &
Johnson's shot, authorized in the United States in February, will also
need boosters.
"You want to get out ahead of the virus," Anthony Fauci, President Joe
Biden's chief medical adviser, told reporters. "If you wait for
something bad to happen before you respond to it, you find you're
considerably behind your real full capability of being responsive."
The booster shots, officials said, initially will focus on healthcare
workers, nursing home residents and older people - among the first
groups to be vaccinated in late 2020 and early 2021.
The news drew support from both U.S. House Speaker Nancy Pelosi and
Senate Republican Leader Mitch McConnell, who said he "absolutely"
planned to get a third shot.
Shares of Pfizer rose around 1.65% in midday trading. Moderna shares
dropped around 2.8% and J&J fell 0.5%.
There is mounting evidence that protection from COVID-19 vaccines wanes
after six or more months, especially in older people with underlying
health conditions. The officials cited this in their decision on
boosters, but stressed that the U.S.-authorized shots have proven
"remarkably effective" in reducing the risk of severe disease,
hospitalizations and deaths.

More than a million Americans sought an extra vaccine dose before the
official decision on boosters was announced, according to federal data.
U.S. officials previously authorized a third dose of the Pfizer/BioNTech
and Moderna vaccines for people with weak immune systems.
The U.S. announcement defies guidance from the World Health
Organization, whose chief scientist said current data does not indicate
the need for booster shots.
In recent weeks, several other countries have decided to offer booster
shots to older adults and people with weak immune systems, including
Israel, Germany and France. European Union officials said on Wednesday
they do not yet see a need to give booster shots to the general
population.
U.S. officials do not expect a serious uptick in hospitalizations and
deaths among vaccinated people until at least eight months after their
initial inoculation, U.S. Surgeon General Vivek Murthy said.
[to top of second column]
|

A healthcare worker prepares a syringe with the Moderna COVID-19
Vaccine at a pop-up vaccination site operated by SOMOS Community
Care during the COVID-19 pandemic in Manhattan in New York City, New
York, U.S., January 29, 2021. REUTERS/Mike Segar/File Photo

A new study conducted in New York and cited by U.S.
Centers for Disease Control and Prevention chief Rochelle Walensky
found that COVID-19 vaccine effectiveness dropped from around 92% in
May to around 80% more recently.
Vaccines are generally less effective against the Delta variant now
dominant in the United States, Walensky added, citing a study of
U.S. nursing homes showing a 53% rate of vaccine effectiveness
against Delta.
DELTA VARIANT CONCERNS
The United States leads the world in reported COVID-19 cases and
deaths, with around 500 Americans dying daily. Daily U.S. cases
soared from fewer than 10,000 in early July to more than 150,000 in
August as the Delta variant took hold.
The new cases include vaccinated people, though they are far less
likely to experience severe disease or death than the unvaccinated.
A new study by an Israeli healthcare provider found a third
dose of the Pfizer/BioNTech shot is 86% effective in people over age
60. It followed another Israeli study that showed evidence of waning
immunity from COVID-19 vaccines in the months after inoculation.
World Health Organization officials contend that vaccine doses
should first go to people in poorer countries who have yet to
receive an initial inoculation.

"We are planning to hand out extra life jackets to people who
already have life jackets, while we are leaving other people to
drown without a single life jacket. That's the reality," Mike Ryan,
WHO's chief emergency expert, told a news conference, referring to
booster shots.
Biden said the administration has been planning for boosters for
months and the recommendation will not diminish its vaccine
donations abroad, amounting to about 200 million shots over the
coming months.
The U.S. booster plan is dependent on the Food and Drug
Administration determining that a third dose of the two-dose
vaccines is safe and effective, and a favorable recommendation from
CDC advisers.
(Reporting by Carl O'Donnell in New York and Ahmed Aboulenein in
Washington; additional reporting by Jarrett Renshaw and Susan Heavey
in Washington, D.C., Francesco Guarascio in Brussels and Stephanie
Nebehay in Geneva; Editing by Will Dunham and Grant McCool)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |